New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

(2010) B. Ahren et al.   DIABETES CARE

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

(2009) Charles Thomas et al.   Cell Metabolism

TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action

(2009) D. T. Villareal et al.   DIABETES

Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia

(2009) M. Pruski et al.   DIABETES CARE

A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion

(2009) S. A. Schäfer et al.   DIABETOLOGIA

Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function

(2009) Luan Shu et al.   HUMAN MOLECULAR GENETICS

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

(2008) D. M. Nathan et al.   DIABETOLOGIA